Portal de Periódicos da CAPES

Improved clinical outcome after intracoronary administration of bone-marrow-derived progenitor cells in acute myocardial infarction: final 1-year results of the REPAIR-AMI trial

2006; Oxford University Press; Volume: 27; Issue: 23 Linguagem: Inglês

10.1093/eurheartj/ehl388

1522-9645

Volker Schächinger, Sandra Erbs, A. Elsasser, Werner Haberbosch, Rainer Hambrecht, Hans Hölschermann, J. Yu, Roberto Corti, Detlef G. Mathey, C Hamm, T. Suselbeck, Nikos Werner, Jürgen Haase, J. Neuzner, A. Germing, B. Màrk, Birgit Aßmus, Torsten Tonn, Stefanie Dimmeler, Andreas M. Zeiher,

Acute Myocardial Infarction Research

Aims To investigate the clinical outcome after intracoronary administration of autologous progenitor cells in patients with acute myocardial infarction (AMI). Methods and results Using a double-blind, placebo-controlled multicentre trial design, we randomized 204 patients with successfully reperfused AMI to receive intracoronary infusion of bone-marrow-derived progenitor cells (BMCs) or placebo medium into the infarct artery 3–7 days after successful infarct reperfusion therapy. At 12 months, the pre-specified cumulative endpoint of death, myocardial infarction, or necessity for revascularization was significantly reduced in the BMC group compared with placebo (P=0.009). Likewise, the combined endpoint death, recurrence of myocardial infarction, and rehospitalization for heart failure was significantly (P=0.006) reduced in patients receiving intracoronary BMC administration. Intracoronary administration of BMC remained a significant predictor of a favourable clinical outcome by Cox regression analysis, adjusting for classical predictors of poor outcome after AMI. Conclusion Intracoronary administration of BMCs is associated with a significant reduction of the occurrence of major adverse cardiovascular events after AMI. Large-scale studies are warranted to confirm the effects of BMC administration on mortality and morbidity in patients with AMIs.